Biosimilar Transitioning – Guidelines and Educational Resources
Here are some educational resources on biosimilar transitioning that the ORA endorses: Arthritis Consumer Experts (ACE) has produced a special biosimilars education video series, where ACE speaks to medical experts on key patient […]
ORA Guide to Public Drug Coverage
Dr. Felix Leung has developed a comprehensive document explaining public drug coverage for your patients. Please visit this link to access: ORA Guide to Public Drug Coverage […]
MOHLTC Announcement: LU Code for Etanercept Effective July 31, 2019
Effective July 31, 2019. The Edition No. 43 document will be posted on the Ministry’s website http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx by July 31, 2019. Erelzi (etanercept) 25mg/0.5mL, 50mg/mL PFS, Pre-Filled Autoinj (SDZ) LU Code 563 For the treatment […]
Your Role as a Health Information Custodian – Some Facts to Share
There is considerable value in the data stored in electronic medical records (EMRs). A number of external stakeholders including pharma companies and pharmacy networks have expressed interest in exporting these data, better to […]
Now Accepting Applications for the Bensen Models of Care Initiative!
Dr. William Bensen was a respected rheumatologist and mentor to many. He advocated strongly for team-based models of care and his own team in Hamilton (consisting of nurses and pharmacists) delivered exceptional care […]
Sarilumab (Kevzara) is Now Funded by EAP Effective July 9, 2019!
Please be advised that the Kevzara injection is now funded through EAP for the treatment of Rheumatoid Arthritis in adult patients meeting the following criteria: Sarilumab is being used as monotherapy or in combination with […]
New ONLINE Process for Submitting EAP Requests!
The Exceptional Access Program is excited to announce that the Special Authorization Digital Information Exchange (SADIE) service is now available to physicians and nurse practitioners across Ontario! Learn more via this form: 2019-07 […]
Tocilizumab For GCA – EAP Approved
Funding for tocilizumab (Actemra) will be considered for the treatment of new onset or relapsed Giant Cell Arteritis (GCA) through the Exceptional Access Program (EAP) in adult patients meeting all the following criteria: […]
OHIP+ Redesign Update
The MOHLTC has published an FAQ document that may be accessed via this link: FAQ OHIP+ […]
Form For Prescription Drugs Previously Funded Through OHIP+ That Require Prior Authorization From a Private Insurer
On March 29, 2019 representatives from the ORA Board met with the MOHLTC to discuss the new OHIP+. The following information was shared by the Ministry: Form for prescription drugs previously funded through OHIP+ that […]
